Advanced Practice Providers

Burnout

Concierge Medicine

Concierge Medicine 2.0 by Castle Connolly Private Health Partners

Employment Trends

Learning and Development

Locum Tenens, brought to you by LocumLife®

Maintenance of Certification

Careers

Contract Negotiation

Insurance

Malpractice

Risk Management

Legal

Data and Analytics

Device Pipeline and Approvals

Device Regulation and Policy

Earnings and Investment

Emerging Technology

Leaders and Innovators

Medtech Industry Trends

Mergers and Acquisitions

Point of Care

Tech Transfer

Medical Device & Technology

Opinion

Estate Planning

Investing

Retirement Planning

Physician's Money Digest

Industry Trends

Medicare & Medicaid

Pharma Industry

Physician Advocacy

Politics

Policy

Billing and Collections

Payment Models

Practice Valuation

Practice valuation

Reimbursement

Revenue Cycle Management

Practice Finance

Chronic Condition Management

Coding and Documentation

Leadership

Marketing

Patient Relations

Staffing

Vaccines

Practice Management

Cybersecurity

EHRs

Medical Technology

Remote Patient Monitoring

Telehealth

Practice Technology

Screening

100 Years of Medical Economics

Exclusive Content 

Special Reports

News

All News

Money

Physicians Financial News

Technology

Media

Around the Practice

Between The Lines

Clinical Consult

Expert Interviews

Medical Economics Pulse

Medical World News

Off The Charts Podcasts

Physician Report

PrimaryView

Academy

Conferences

Conference Coverage

Conference Listing

Publications

Medical Economics

Supplements And Featured Publications

CME/CE

Job Board

Subscribe

Directories

Financial Advisor Guide

Medical Economics is the leading health care business media brand for physicians, serving our audience of doctors through our print magazine, in-depth features, video interviews, podcasts and more.

About

Advertise

Contact Us

Editorial Staff

Terms and Conditions

Contributor Guidelines

Privacy Policy

Do Not Sell My Personal Information

Facebook

LinkedIn

Business Focus

Career Planning

Electronic Health Records

Personal Finance

Value-based Care

Locum Tenens

Clinical  Focus

Allergy and Immunology

Cardiology

Dermatology

Endocrinology

Gastroenterology

Infectious Disease

Neurology

Pain Management

Pediatrics

Psychiatry

Pulmonology

Rheumatology

Women's Health

Spotlight

The benefits of a physician MBA program

Physician Bootcamp

1rem

Topics

Introducing the Rice Biotech Launch Pad

Why innovation is led by clinicians

Project Thor: A device to transform cancer treatment

Developing an implantable bioreactor

Balancing innovation and patient need

The benefits and challenges of tech transfer

The future of the Rice Biotech Launch Pad

 has set an ambitious course to transform lab discoveries into real-world solutions for patients, and at the center of this effort is 

, its faculty director and a professor of bioengineering at Rice University.

to offer his insights into how Rice University’s incubator fast-tracks promising biotech ventures — from cutting-edge immunotherapies to advanced diagnostic platforms — by pairing clinicians and researchers with entrepreneurs, investors and industry partners.

“Our projects all start with a clinician founder,” Veiseh said. “It’s a problem that a clinician has seen, either in treating their own patients or a trial they ran, that has a technological gap.”

Among the current slate of projects, teams are pushing the boundaries of cell therapy, regenerative medicine and medical device design. From developing new biomaterials that promote tissue healing to harnessing synthetic biology for next-generation cancer treatments, each project is laser-focused on bringing tangible benefits to physicians and patients, according to Veiseh.

The result is a growing pipeline of innovations poised to change the way physicians diagnose and treat complex diseases. Watch our conversation with Veiseh to learn more about the mission of the Rice biotech launch pad, details on some of its projects, trends in tech transfer, and how they manage the balance of targeting innovation that most benefits patients in need.

Veiseh is a professor and CPRIT Scholar in Cancer Research in the Departments of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He is also the Director of 

, a new initiative with a mission to accelerate the translation of Rice University's discoveries and technologies into clinical practice to provide rapid patient access to leading-edge therapeutic products. He leads an interdisciplinary translational research program to engineer and commercialize next-generation cell-based therapeutics for various human diseases. His team leverages the latest techniques in synthetic biology, immunoengineering, and material science to develop innovative cell-based platforms for real-time and feedback-regulated production of biologics. 

Throughout his career, he has authored or co-authored more than 80 peer-reviewed publications, including those in Nature Biotechnology, Nature Materials, Nature Medicine, and Nature Biomedical Engineering. He is an inventor on more than 50 pending or awarded patents. He is also a serial entrepreneur who has co-founded multiple biotechnology companies, collectively attracting ~ $500M in private and public investment capital. Dr. Veiseh has been elected as a fellow of the Controlled release Society and a member of the National Academy of Inventors.

Veiseh received a dual PhD in Materials Science & Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Daniel G. Anderson at MIT and Harvard Medical School.

Videos

Omid Veiseh, PhD, faculty director of the Rice Biotech Launchpad, discusses his organization’s mission to create innovative biotechnology based on patient need.

Fostering clinician-led biotech innovation